Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arjun Joshi

Plastic Surgery within the Head & Neck Washington, DC Medical Doctor

NPI 1619101334 CMS profile 118733

2300 M St Nw Fl 4, Washington, DC 20037

Open in the dashboard

General payments

$11,089

59 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arjun Joshi of Washington, DC is reported in the CMS Open Payments database as having received $11,089 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,129 17
2024 General $503 7
2023 General $534 11
2022 General $2,019 10
2021 General $6,469 7
2020 General $62 2
2019 General $373 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arjun Joshi
  • Plastic Surgery within the Head & Neck median
  • Middle half of Plastic Surgery within the Head & Neck
  • National median

In program year 2025, general payments to Arjun Joshi were reported at $1,129. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.

Show as a table
Year Arjun Joshi Plastic Surgery within the Head & Neck median Middle half National median
2019 $373 $200 $82–$550 $163
2020 $62 $120 $46–$330 $114
2021 $6,469 $166 $60–$382 $132
2022 $2,019 $208 $83–$530 $149
2023 $534 $202 $77–$538 $160
2024 $503 $260 $99–$645 $164
2025 $1,129 $237 $103–$520 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cook Incorporated $8,143 7 payments
  2. Stryker Corporation $582 6 payments
  3. Integra LifeSciences Corporation $562 7 payments
  4. Inspire Medical Systems, Inc. $282 4 payments
  5. Atos Medical Inc $235 3 payments
  6. DePuy Synthes Sales Inc. $153 4 payments
  7. Davol Inc. $151 1 payment
  8. Intersect ENT, Inc. $147 1 payment
  9. Aerin Medical Inc. $145 1 payment
  10. Baxter Healthcare $136 1 payment
  11. Other $554 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,405 5 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,738 2 payments
  3. Food and Beverage $2,929 51 payments
  4. Gift $17 1 payment
Products named General payments · program years 2019–2025
  1. Cook-Swartz $8,167 8 payments
  2. VSP SYSTEM, VSP CRANIAL $357 3 payments
  3. INSPIRE $282 4 payments
  4. Integra Recon-Skin And Wound $237 3 payments
  5. Integra Recon-Skin And Wound $237 3 payments
  6. Integra Recon-Skin And Wound $237 3 payments
  7. INTEGRA DERMAL REGENERATION TEMPLATE $237 3 payments
  8. PRIMATRIX $237 3 payments
  9. Provox Life Home HME $235 3 payments
  10. ACCLARENT AERA $202 3 payments
  11. Other $2,533 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

61

Median for Otolaryngology: 297

Drug cost

$813

Median for Otolaryngology: $6,314

Branded share of claims

37.7%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 23 $334
Omeprazole Generic 15 $314
Oxycodone Hcl Generic 12 $95
Levothyroxine Sodium Generic 11 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$217,103

Medicare's payments for the services billed

Medicare patients

334

Average age 74

Services billed

1,327

162 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 46%
Ischemic heart disease 30%
Diabetes 28%
COPD 23%
Chronic kidney disease 21%
Cancer 20%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery within the Head & Neck in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record